Unknown

Dataset Information

0

Effects of the combinations of amlodipine/valsartan versus losartan/hydrochlorothiazide on left ventricular hypertrophy as determined with magnetic resonance imaging in patients with hypertension.


ABSTRACT: BACKGROUND:Left ventricular hypertrophy (LVH), a marker of cardiac end-organ damage, is frequently found in patients with arterial hypertension and is associated with cardiovascular and cerebrovascular morbidity and mortality. Therefore, LVH regression is an important treatment goal. For amlodipine plus valsartan (A/V) no specific study on LVH has been reported to date. METHODS:Prospective, open-label, randomized parallel-group study. Patients with essential hypertension and LVH were randomized to 52-week treatment with A/V 10/160?mg (n?=?43) or the active comparator losartan/HCT 100/25?mg (L/H, n?=?47). Add-on medication was allowed in case of inadequate blood pressure control. LV parameters were measured by cardiovascular magnetic resonance imaging (MRI), and adjudicated in a blinded manner. Study identifiers were NCT00446563 and EudraCT 2006-001977-17. RESULTS:In addition to the study treatment, 35% of patients in the A/V group and 49% in the L/H group received additional antihypertensive medication. Compared to baseline, both treatments reduced measures of LVH significantly after 52 weeks (e.g. LV mass index in the A/V group from 64.7?g/m(2) by -3.5?g/m(2), in the L/H group from 69.1?g/m(2) by -4.4?g/m(2), p?

SUBMITTER: Bruder O 

PROVIDER: S-EPMC4980731 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature

altmetric image

Publications

Effects of the combinations of amlodipine/valsartan versus losartan/hydrochlorothiazide on left ventricular hypertrophy as determined with magnetic resonance imaging in patients with hypertension.

Bruder Oliver O   Jensen Christoph J CJ   Bell Michael M   Rummel Reinhard R   Boehm Guenter G   Klebs Sven S   Sieder Christian C   Senges Jochen J  

Journal of drug assessment 20111216 1


<h4>Background</h4>Left ventricular hypertrophy (LVH), a marker of cardiac end-organ damage, is frequently found in patients with arterial hypertension and is associated with cardiovascular and cerebrovascular morbidity and mortality. Therefore, LVH regression is an important treatment goal. For amlodipine plus valsartan (A/V) no specific study on LVH has been reported to date.<h4>Methods</h4>Prospective, open-label, randomized parallel-group study. Patients with essential hypertension and LVH w  ...[more]

Similar Datasets

| S-EPMC8030834 | biostudies-literature
| S-EPMC9793986 | biostudies-literature
| S-EPMC3950308 | biostudies-literature
| S-EPMC3245686 | biostudies-literature
| S-EPMC6507185 | biostudies-literature
| S-EPMC3204831 | biostudies-other
| S-EPMC6156014 | biostudies-literature
| S-EPMC3175529 | biostudies-literature
| S-EPMC4098842 | biostudies-literature
| S-EPMC3499934 | biostudies-literature